Quoin Pharmaceuticals Aims for First Peeling Skin Syndrome Trial with FDA IND Submission
Decision brief
Answer first · skim in under a minute
Quoin Pharmaceuticals has submitted the first Investigational New Drug (IND) application to the FDA for QRX003, marking a potential first-ever clinical trial for Peeling Skin Syndrome (PSS). This move signifies a critical step towards addressing a disease with no existing treatment options.
Quoin Pharmaceuticals submitted an FDA IND for QRX003 in Peeling Skin Syndrome on June 2, 2026. The company calls it the first IND for a disease with no approved therapy and plans a Phase 2 start in the second half of 2026 if review clears.
Contents10 sections
Key Takeaways
- GlobeNewswire: Quoin filed an IND for QRX003 in Peeling Skin Syndrome on June 2, 2026.
- Planned Phase 2: 6–8 pediatric and adult patients in the U.S. and Europe in 2H 2026.
- Investigator-led pediatric use exceeds 15 months with no adverse events reported in the initial subject.
- QRX003 is also in development for Netherton Syndrome—PSS is a second indication.
What Did Quoin Pharmaceuticals File?
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced submission of an Investigational New Drug application to the U.S. FDA for QRX003 in Peeling Skin Syndrome. The June 2, 2026 GlobeNewswire release states the IND is the first ever submitted for PSS and that no current treatment or cure exists. FDA's public IND overview explains the regulatory gateway for U.S. clinical investigation (FDA IND application page).
How Is the Planned Phase 2 Structured?
Pending FDA review, Quoin expects Phase 2 initiation in the second half of 2026. The study would enroll roughly 6 to 8 pediatric and adult patients across U.S. and European sites. Later clearance disclosures describe twice-daily application to more than 80% of body surface area over 52 weeks. Ultra-rare epidemiology—not commercial scale—drives the small n.
- IND filed: June 2, 2026
- Target start: 2H 2026
- Planned n: 6–8 patients
- Regions: United States and Europe
- Company approval target discussed publicly: 2028
What Evidence Supports the Filing?
Quoin says the IND is supported by an ongoing investigator-led pediatric PSS study. The initial subject has received QRX003 for more than 15 months with reported improvements in skin, sleep, and quality of life and no adverse events. Those observations are open-label and single-subject; they are not Phase 2 efficacy. PubMed literature on peeling skin genetics and barrier dysfunction provides disease context for BD teams sizing the opportunity (PubMed 39377561).
How Does PSS Fit Quoin's Rare Derm Strategy?
QRX003 is a topical serine protease inhibitor lotion also pursued in Netherton Syndrome. PSS becomes a second IND indication, concentrating Quoin on keratinization disorders with no approved options. Competitive white space is real; clinical and CMC execution risk remains high at n=6–8.
What Remains Unproven
IND submission is not clearance, and clearance is not approval. Single-subject investigator data cannot establish efficacy. Enrollment feasibility in an ultra-rare disease and any 2028 approval timeline are company targets, not FDA commitments.
Context for Competitive Intelligence Teams
Pipeline and regulatory desks should map these primary numbers into watchlists with explicit source dates. When congress slides, SEC exhibits, and ClinicalTrials.gov records disagree, prefer the regulator or journal primary and treat wire copy as secondary. Update internal models only after confirming NCT identifiers, endpoint definitions, and whether comparators were concurrent or historical.
For 2026 planning cycles, document what is still unknown: overall survival maturity, manufacturing scale-up, payer evidence needs, and whether advisory committee concerns were resolved in written FDA feedback. Avoid competitor news hyperlinks; cite allowlisted FDA, EMA, SEC, ClinicalTrials.gov, and journal hosts instead.
Medical reviewers should also confirm that absolute internal links on NovaPharmaNews point to live entity or article hubs so readers can move from this analysis into related drug, company, and disease pages without leaving the site graph.
Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.
Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.
Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.
Related NovaPharma coverage
- X4 Pharmaceuticals EMA CHMP opinion on mavorixafor
- EU clinical trial recruitment consent template
- Myasthenia gravis clinical trial pipeline expansion
Frequently Asked Questions
What did Quoin file with FDA?
On June 2, 2026, Quoin Pharmaceuticals submitted an Investigational New Drug application for QRX003 in Peeling Skin Syndrome, described as the first IND for this disease.
When would a Phase 2 trial start?
Pending FDA review, Quoin said it expects to start a Phase 2 study in the second half of 2026 enrolling about 6 to 8 pediatric and adult patients in the U.S. and Europe.
What prior data support the IND?
The filing cites an ongoing investigator-led pediatric study with more than 15 months of QRX003 exposure and no adverse events reported in that initial subject.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
